Evidence map›Paper›PMID 35867916›Full record

ArticleBiomedica : revista del Instituto Nacional de Salud2022

Chagas disease reactivation after autologous stem cell transplant. Case report and literature review

Juan David Rojas, Mario Pereira, Bibiana Martínez, Julio César Gómez, Sonia Isabel Cuervo

Abstract read
In one paragraph

Article in Biomedica : revista del Instituto Nacional de Salud, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Chagas disease in immunocompromised patients.Clinical microbiology reviews · 2024
    Review
  2. Article
  3. Article
  4. Current tropical medicine reports · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juan David RojasDepartamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia; Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas, Bogotá, D.C., Colombia. juandrojas269@gmail.com.
Mario PereiraGrupo de Trasplante de Precursores Hematopoyéticos, Instituto Nacional de Cancerología E.S.E., Bogotá, D.C., Colombia. biomedica@ins.gov.co.
Bibiana MartínezGrupo de Patología, Instituto Nacional de Cancerología E.S.E., Bogotá, D.C., Colombia. biomedica@ins.gov.co.
Julio César GómezGrupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas, Bogotá, D.C., Colombia; Grupo de Infectología, Instituto Nacional de Cancerología E.S.E., Bogotá, D.C., Colombia. biomedica@ins.gov.co.
Sonia Isabel CuervoDepartamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia; Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas, Bogotá, D.C., Colombia; Grupo de Infectología, Instituto Nacional de Cancerología E.S.E., Bogotá, D.C., Colombia. biomedica@ins.gov.co.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chagas disease is an endemic parasitic infection in Latin America transmitted by triatomines. It is associated with risk factors such as poverty and rurality. After acute infection, a third of patients will present target organ involvement (heart, digestive tract, central nervous system). The remaining two thirds remain asymptomatic throughout their life. Pharmacological immunosuppression breaks the balance between the immune system and the parasite, favoring its reactivation. Clinical case: We present the case of a 58-year-old man from a Colombian rural area with a diagnosis of multiple myeloma refractory to the first line of treatment who required a new chemotherapy scheme and consolidation with autologous stem cell transplant. During the post-transplant period, he suffered from febrile neutropenia. Initial microbiological studies were negative but the peripheral blood smear evidenced trypomastigotes in blood. With a diagnosis of acute Chagas disease in a post-transplant patient, benznidazole was started. The evolution of the patient was satisfactory. Conclusions: Positive serology prior to transplantation makes it necessary to rule out reactivation of the pathology in the setting of febrile neutropenia. More studies are required to determine tools for estimating the probability of reactivation of the disease and defining the best cost-risk-benefit relation for the prophylactic therapy.

Indexed as

NeutropeniaHumansRetrospective StudiesChagas diseasefebrile neutropeniahematopoietic stem cell transplantationimmunosuppressionmultiple myelomaparasitic diseasesTrypanosoma cruzi

Identifiers

PMID35867916
PMCPMC9302074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.